US Patent 10,428,059: Claim Scope, Patent Strength, Exclusivity and Competitive Landscape

US Patent 10,428,059 protects methods of treating scleroderma or systemic lupus erythematosus with a defined class of small molecules that modulate IL-1 receptor-mediated disease. The strongest protection is concentrated in claim 2, which covers two expressly identified naphthyl-substituted pyridopyrimidine compounds. The patent does not claim an approved drug, a specific formulation, or a biologic product.

The patent creates a potential method-of-use barrier for clinical development and labeling of the claimed compounds in scleroderma or lupus. It does not, based on the claims provided, block all uses of the compounds, all IL-1 pathway inhibitors, or the manufacture of the compounds outside an infringing treatment context.

What does US Patent 10,428,059 claim?

The issued claims form an eight-claim method-of-treatment hierarchy.

Claim	Subject matter	Commercial significance
1	Treating scleroderma or lupus in a mammal with a compound of formula XI	Principal genus claim
2	Two specifically named naphthyl pyridopyrimidine compounds	Narrowest and most concrete compound-use claim
3	Treatment with at least one additional therapeutic agent	Combination-treatment genus
4	Specific co-therapies, including anakinra, rilonacept, methotrexate, prednisone, rituximab and a tyrosine kinase inhibitor	Expands coverage across existing treatment regimens
5	Co-administration of the claimed compound and another therapeutic agent	Covers concurrent dosing
6	Administration before or after another therapeutic agent	Covers sequential regimens
7	Use of a pharmaceutical composition	Adds formulation context without defining a particular formulation
8	Treatment of a human	Narrows the independent method to human use

Claim 1 requires four elements:

A method of relieving or improving an IL-1R-mediated disease or disorder.
The disease must be scleroderma or systemic lupus erythematosus.
The patient must be a mammal.
The administered compound must satisfy formula XI, including the specified R1, R2 and R3 substitutions.

The formula permits each R1 group to be hydrogen or methyl, R2 to be oxygen or NH, and R3 to be an optionally substituted phenyl or naphthyl group. The claim therefore covers a chemical genus rather than only the two compounds recited in claim 2.

What compounds are specifically protected?

Claim 2 identifies:

1,3-dimethyl-5-(naphthalen-1-yl)-5,11-dihydro-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione; and
2-amino-5-(naphthalen-1-yl)-5,11-dihydro-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-4,6-dione.

The claim also covers salts, tautomers and solvates of those compounds. That language can extend protection beyond a single neutral crystalline form, but it does not automatically cover every polymorph, prodrug, metabolite or formulation unless the relevant form falls within the claimed compound language.

How broad is the claim 1 chemical genus?

Claim 1 is broader than claim 2 but narrower than a general IL-1 inhibitor claim. It is constrained by the fused heterocyclic scaffold shown in formula XI and by the permitted substituents.

The principal breadth comes from:

Two alternatives for each R1 group;
Two alternatives for R2;
Phenyl and naphthyl alternatives for R3;
Optional substitution on phenyl or naphthyl;
Coverage of salts, tautomers and solvates;
Treatment of either scleroderma or lupus.

The chemical scope is not unlimited. A compound with a different core, a different carbonyl arrangement, a non-permitted aromatic group, or a different substitution pattern would fall outside claim 1 unless captured by another claim or doctrine of equivalents.

A key claim-construction issue is the meaning of “optionally substituted phenyl or naphthyl.” The scope normally includes the unsubstituted ring and permitted substituted versions, but the patent specification and prosecution history would control which substituents are supported and how the phrase is interpreted. The claims supplied do not identify the complete substituent list.

What disease indications are covered?

The issued claims expressly identify:

Scleroderma; and
Systemic lupus erythematosus, also called lupus or SLE.

The disease limitation is material. A use directed solely to rheumatoid arthritis, osteoarthritis, gout, inflammatory bowel disease or another IL-1-associated condition would not literally satisfy claim 1 unless the use also falls within scleroderma or lupus.

“Scleroderma” may raise scope questions because it can refer broadly to systemic sclerosis or localized scleroderma. The patent specification and prosecution record would be relevant to determining whether the term was used broadly or primarily to describe systemic sclerosis. Claim 4 lists therapies commonly associated with systemic sclerosis and autoimmune disease, but the claim text alone does not resolve the scope of “scleroderma.”

What combination therapies are protected?

Claims 3 through 6 cover treatment in combination with at least one additional therapeutic agent. Claim 4 lists:

Anakinra;
Rilonacept;
Azathioprine;
Methotrexate;
Bosentan;
Etanercept;
Halofuginone;
Iloprost;
Cyclophosphamide;
Cyclosporin A;
Mycophenolate mofetil;
Intravenous immunoglobulin;
Pirfenidone;
Prednisone;
Rituximab;
Beta-glucan peptides;
Basiliximab;
Sirolimus;
Alefacept;
Terguride;
Pomalidomide; and
A tyrosine kinase inhibitor.

Claim 5 covers co-administration. Claim 6 covers administration in a defined period before or after the other therapy. Neither claim, as provided, requires a particular dose ratio, sequence, treatment duration or demonstrated synergy.

This creates potentially broad regimen coverage. A clinical protocol using a covered compound with prednisone, mycophenolate mofetil or rituximab could implicate claims 3 through 6 if the use is directed to scleroderma or lupus and the compound satisfies formula XI.

The claims do not require the second agent to act through IL-1R. A listed co-therapy may therefore qualify based on its use in the claimed regimen rather than its molecular mechanism.

What formulation patents are covered?

Claim 7 recites administration of the compound “formulated as a pharmaceutical composition.” It does not specify:

Tablet, capsule, injectable or topical dosage form;
Excipients;
Particle size;
Salt form;
Crystalline form;
Release profile;
Dose strength;
Stability characteristics; or
A particular manufacturing process.

Claim 7 is therefore not a conventional formulation claim. It is a dependent method claim that requires the administered compound to be in a pharmaceutical composition.

The patent may have separate composition, formulation or process claims in related family members, but those cannot be assumed from the issued claims provided. A product developer should distinguish this method patent from later patents directed to polymorphs, solid dispersions, dosage forms, combination tablets or manufacturing processes.

When does US Patent 10,428,059 lose exclusivity?

The patent was granted on October 1, 2019. Its enforceable term depends on the earliest effective nonprovisional priority date, any terminal disclaimer, patent-term adjustment and patent-term extension. Those dates are not stated in the claims supplied.

The ordinary US patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156. The grant date is not the expiration date. A definitive expiry analysis requires the patent’s continuity data and Patent Center term information. [1][2]

Because the patent claims a development-stage small molecule rather than an approved product, FDA regulatory exclusivity does not appear to establish a separate commercial blocking period. Patent exclusivity and FDA exclusivity are separate rights.

What is the Orange Book status?

US Patent 10,428,059 should not be treated as an Orange Book-listed patent merely because it claims pharmaceutical treatment. Orange Book listing is associated with an approved new drug application and patents that claim the approved drug, its formulation or an approved method of use. [3]

The claimed compounds do not appear from the claim text to correspond to an identified FDA-approved active ingredient. The patent therefore does not create a conventional Hatch-Waxman abbreviated new drug application barrier unless one of the compounds later becomes the subject of an approved NDA and the patent is properly submitted and accepted for listing.

The practical implications are:

No automatic Paragraph IV pathway exists solely because this patent was granted.
A generic applicant would need an approved reference listed drug before filing an ANDA.
If the compounds remain unapproved, development would ordinarily proceed through an NDA pathway rather than an ANDA.
A Paragraph IV certification could become relevant only if the patent is listed against an approved reference product.

Are there Paragraph IV challenges or patent litigation?

The claims provided do not establish any Paragraph IV certification, district court litigation, inter partes review, post-grant review or settlement agreement.

There is no basis to infer a generic challenge from the existence of the patent. The relevant litigation risks would arise if:

A company develops one of the claimed compounds for lupus or scleroderma;
The compound reaches an NDA filing or approval;
The patent is listed against the approved product; and
A later applicant files an ANDA with a Paragraph IV certification.

For a development-stage asset, the more immediate risk is an anticipatory declaratory-judgment action or a patent-validity challenge during licensing or clinical development. The most important records are USPTO Patent Center, PTAB proceedings, PACER and the federal court docket for the patent’s district. [1][4]

How strong is the patent estate?

Strengths

The patent has several commercially relevant strengths:

Claim 2 names two concrete compounds, reducing ambiguity over the protected species.
The indication is limited to commercially important autoimmune diseases.
The claims cover salts, tautomers and solvates.
Combination claims cover commonly used background therapies.
Claims 5 and 6 address both concurrent and sequential treatment.
Claim 8 expressly reaches human treatment.

Weaknesses

The principal weaknesses are:

The patent claims treatment methods, not ownership of the entire chemical scaffold.
The disease limitation restricts use outside scleroderma and lupus.
Claim 1 depends on adequate written-description and enablement support across the full genus.
“Optionally substituted phenyl or naphthyl” may create scope and support disputes.
The claims do not establish a specific dose, biomarker, patient subgroup or clinical response threshold.
Claim 7 adds little formulation exclusivity because it does not define a formulation.
A competitor could potentially develop a structurally distinct IL-1 pathway inhibitor.
A competitor may avoid literal infringement by pursuing another indication or a non-covered compound, although induced-infringement theories would depend on labeling and conduct.

Validity pressure points

A validity challenge would likely focus on:

Anticipation by prior disclosures of the named compounds and their therapeutic use;
Obviousness based on known IL-1R biology, known autoimmune indications and known heterocyclic compounds;
Written description for the full formula XI genus;
Enablement across the permitted R1, R2 and R3 combinations;
Indefiniteness involving disease terminology or the scope of optional substitution;
Patent eligibility under Section 101, although treatment-method claims involving a specific drug class generally present a different issue from claims directed only to a natural law.

The claims are stronger against a product that uses one of the two expressly named compounds in lupus or scleroderma than against a structurally remote compound within the broader IL-1 inhibitor field.

How does this patent compare with IL-1 biologic estates?

Product or class	Mechanism	Relation to US 10,428,059	Biosimilar or generic risk
Anakinra	Recombinant IL-1 receptor antagonist	Listed as a potential combination therapy in claim 4	Biosimilar competition is relevant to anakinra, not to the claimed small molecules
Rilonacept	IL-1 trap	Listed as a potential combination therapy	Biologic exclusivity and biosimilar issues are separate
Canakinumab	Anti-IL-1β antibody	Not listed in the supplied claims	Separate antibody patent and regulatory estate
Etanercept	TNF inhibitor	Listed as a potential combination therapy	Separate biologic estate
Methotrexate and prednisone	Immunosuppressive and anti-inflammatory therapies	Listed as combination agents	Generic competition is established or mature
Tyrosine kinase inhibitors	Broad drug class	Covered only when used as the additional agent in the claimed regimen	Scope depends on the specific regimen and compound

US Patent 10,428,059 does not claim an IL-1 antibody, receptor antagonist protein or biosimilar. Biosimilar competition is therefore not a direct invalidation or expiration event for this patent.

What generic or competitive entry scenarios exist?

Scenario 1: Direct development of a named compound

A company administering either claim 2 compound for lupus or scleroderma would face the clearest infringement risk. The risk would extend to salts, tautomers and solvates if they fall within the claim.

Scenario 2: Development of a different formula XI compound

A different compound within claim 1 could still infringe if it satisfies the structural limitations and is administered for the claimed diseases. The commercial risk would depend on whether the compound is also supported by the patent’s specification and whether claim 1 survives validity scrutiny.

Scenario 3: Development for another indication

A compound administered solely for an unclaimed disease may avoid literal infringement of the supplied claims. Labeling, clinical-trial materials and promotional conduct would be important in assessing induced infringement.

Scenario 4: Combination treatment

Use with prednisone, methotrexate, rituximab or mycophenolate mofetil could trigger dependent claims even if the base compound is otherwise being developed under claim 1.

Scenario 5: Process or formulation competition

Manufacturing a compound is not, by itself, an act that necessarily practices these method claims. Separate composition, process or formulation patents could create additional barriers, but they are not established by the claims provided.

What is the commercial exposure?

The claims do not identify an approved product, sales, licensee or clinical-stage asset. As a result, the direct revenue exposure attributable to this patent cannot be quantified from the claims alone.

The potential value is option-based:

It could support exclusivity for a novel oral or small-molecule autoimmune therapy.
It may provide leverage in licensing negotiations involving the named compounds.
It could restrict combination-label strategies using standard lupus or systemic-sclerosis therapies.
It does not independently establish market access, clinical efficacy or FDA approval.
Its commercial value depends on whether the claimed compounds have clinical development, licensing or regulatory activity outside the patent record.

Key Takeaways

US Patent 10,428,059 is primarily a method-of-use patent for treating scleroderma or lupus with formula XI compounds.
Claim 2 is the clearest commercial boundary because it names two specific compounds.
Claims 3 through 6 extend risk to combination and sequential treatment with numerous existing therapies.
Claim 7 is a limited pharmaceutical-composition method claim, not a detailed formulation patent.
The patent is not, based on the claims supplied, an Orange Book product patent or a biosimilar patent.
Paragraph IV risk would arise only if a claimed compound became an approved reference product and the patent were listed.
The main validity questions concern genus support, enablement, obviousness and the scope of optional aromatic substitution.
Manufacturing a covered compound does not automatically infringe the supplied method claims.
Patent expiration cannot be fixed from the grant date alone; continuity, terminal-disclaimer and patent-term-adjustment records control.

FAQs

Does US Patent 10,428,059 cover anakinra itself?

No. Anakinra appears as a potential combination therapy in claim 4. The patent does not claim anakinra as an active ingredient or biologic product.

Can a company use the claimed compounds for rheumatoid arthritis?

The supplied claims expressly identify scleroderma and lupus. Use solely for rheumatoid arthritis would not literally satisfy the stated disease limitation.

Does claim 7 protect a tablet containing one of the compounds?

Claim 7 covers the claimed method when the compound is formulated as a pharmaceutical composition. It does not define a tablet, excipient, release profile or manufacturing process.

Could a salt of one of the named compounds fall within claim 2?

Yes. Claim 2 expressly includes salts, tautomers and solvates of the two named compounds.

Does the patent block all IL-1 receptor inhibitors?

No. It covers the claimed formula XI compounds when used in the claimed treatment methods. Other chemical classes and biologic IL-1 pathway inhibitors are outside the supplied claims unless covered by separate patents.

References

United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
United States Patent and Trademark Office. (n.d.). Manual of Patent Examining Procedure, Chapter 2700: Patent term. https://www.uspto.gov/web/offices/pac/mpep/mpep-2700.html
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
United States Patent and Trademark Office. (n.d.). Patent Trial and Appeal Board. https://www.uspto.gov/about-us/organizational-offices/office-general-law/patent-trial-and-appeal-boardptab

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	⤷ Start Trial	2037-10-06
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	May 12, 1998	⤷ Start Trial	2037-10-06
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	January 2, 2003	⤷ Start Trial	2037-10-06
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 2, 1998	⤷ Start Trial	2037-10-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,428,059

Summary for Patent: 10,428,059